𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

✍ Scribed by Steven R Cummings; Michael McClung; Jean-Yves Reginster; David Cox; Bruce Mitlak; John Stock; Messan Amewou-Atisso; Trevor Powles; Paul Miller; José Zanchetta; Claus Christiansen

Publisher
American Society for Bone and Mineral Research
Year
2010
Tongue
English
Weight
97 KB
Volume
26
Category
Article
ISSN
0884-0431

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Arzoxifene is a selective estrogen receptor modulator (SERM) that has been shown to be more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. In a randomized, blinded trial, women aged 60 to 85 years with osteoporosis, defined as a femoral neck or lumbar spine bone mineral density T‐score of −2.5 or less or a vertebral fracture, and women with low bone mass, defined as a bone density T‐score of −1.0 or less and above −2.5, were assigned to arzoxifene 20 mg or placebo daily. The primary endpoints were new vertebral fracture in those with osteoporosis and invasive breast cancer in the overall population. After 3 years, the cumulative incidence of vertebral fractures in patients with osteoporosis was 2.3% lower in the arzoxifene group than in the placebo group, a 41% relative risk reduction [95% confidence interval (CI) 0.45–0.77, p < .001]. In the overall population, the cumulative incidence of invasive breast cancer over 4 years was reduced by 1.3%, with a 56% relative reduction in risk (hazard ratio = 0.44, 95% CI 0.26–0.76, p < .001); there was no significant decrease in nonvertebral fracture risk. Arzoxifene increased the cumulative incidence of venous thromboembolic events by 0.7%, with a 2.3‐fold relative increase (95% CI 1.5–3.7). Like other SERMs, arzoxifene decreased vertebral fractures and invasive breast cancer while the risk of venous thromboembolic events increased. © 2011 American Society for Bone and Mineral Research.

📜 SIMILAR VOLUMES

Use of aromatase inhibitors in postmenop
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer
✍ Roseman, Barry J.; Buzdar, Aman U.; Singletary, S. Eva 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB 👁 2 views

Surgeons have been involved in the management of metastatic breast cancer since the technique of ovarian ablation was introduced in 1896. However, as newer hormonal and chemotherapeutic regimens were developed, drug therapy gradually replaced surgery as the preferred treatment for metastatic breast

Clinical development of estrogen modulat
Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women
✍ Julia A. Lawrence; Phyllis B. Malpas; Caroline C. Sigman; Gary J. Kelloff 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 2 views

Tamoxifen has proven to be beneficial in the chemoprevention of breast cancer in women at increased risk for the disease. Other compounds that mediate the estrogen pathway remain to be tested for clinical efficacy. The mechanism of action, efficacy, and dose response of the estrogen modulators is de

Mammographic density, plasma vitamin D l
Mammographic density, plasma vitamin D levels and risk of breast cancer in postmenopausal women
✍ Angela K. Green; Susan E. Hankinson; Elizabeth R. Bertone-Johnson; Rulla M. Tami 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 151 KB 👁 2 views

## Abstract Mammographic density is a strong risk factor for breast cancer, but the underlying biology for this association is unknown. Studies suggest that vitamin D may reduce breast cancer risk and dietary vitamin D intake has been associated with reduced breast density. We conducted a case–cont